Limitations in the use of rifampicin-gelatin grafts against virulent organisms

Journal of Vascular Surgery

Volumn 35, Issue 4, 2002, Pages 779-785

  Koshiko, Susumu ^a,b   Sasajima, Tadahiro ^a,b   Muraki, Senichi ^a,b   Azuma, Nobuyoshi ^a,b   Yamazaki, Kohsuke ^a,b   Chiba, Kaoru ^a,b   Tachibana, Mineji ^a,b   Inaba, Masashi ^a,b  

^a Asahikawa Medical University ^*

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BLOOD VESSEL GRAFT; CONTROLLED STUDY; DOG; ESCHERICHIA COLI; EXPERIMENTAL MODEL; GRAFT INFECTION; GRAFT PATENCY; HISTOPATHOLOGY; IN VITRO STUDY; INFECTION SENSITIVITY; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; VIRULENCE; ANIMAL; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL TRANSPLANTATION; DRUG EFFECT; ENTEROBACTER INFECTION; INFECTION; MICROBIOLOGICAL EXAMINATION; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TIME;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; DOGS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GELATIN; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PROSTHESIS-RELATED INFECTIONS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TIME FACTORS;

EID: 0036546298     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2002.121850     Document Type: Article

References (30)

1. O'Hara PJ, Hertzer NR, Beven EG, Krajewski LP. Surgical management of infected abdominal aortic grafts: review of a 25-year experience. J Vasc Surg 1986;3:725-31.
2. Bandyk DF. Infection in prosthetic vascular grafts. In: Rutherford RB, ed. Vascular surgery. 5th edition. Philadelphia: WB Saunders; 2000. p. 733-51.
3. Coselli JS, Crawford ES, Williams TW, Bradshaw MW, Wiemer DR, Harris RL, et al. Treatment of postoperative infection of ascending aorta and transverse aortic arch, including use of viable omentum and muscle flaps. Ann Thorac Surg 1990;50:868-81.
4. Shue WB, Worosilo SC, Donetz AP, Trooskin SZ, Harvey RA, Greco RS. Prevention of vascular prosthetic infection with an antibiotic-bonded Dacron graft. J Vasc Surg 1988;8:600-5.
5. Kinney EV, Bandyk DF, Seabrook GA, Kelly HM, Towne JB. Antibiotic-bonded PTFE vascular grafts: the effect of silver antibiotic on bioactivity following implantation. J Surg Res 1991;50:430-5.
6. Chervu A, Moore WS, Chvapil M, Henderson T. Efficacy and duration of antistaphylococcal activity comparing three antibiotics bonded to Dacron vascular grafts with a collagen release system. J Vasc Surg 1991;13:897-901.
7. Colburn MD, Moore WS, Chvapil M, Gelaber HA, Quinones-Baldrich WJ. Use of an antibiotic-bonded graft for in situ reconstruction after prosthetic graft infection. J Vasc Surg 1992;16:651-60.
8. Yao JDC, Moellering RC Jr. Antibacterial agents, in antimicrobial agents and susceptibility testing. In: Murray PR, et al, eds. Manual of clinical microbiology. 7th edition. Washington, DC: ASM Press; 1999. p. 1474-504.
9. Sano K, Tunakawa N. Chemistry of rifampicin. Med Treatment 1970;23(S-6):928-35.
10. Brissonniere OG, Leport C, Bacourt F, Lebrault C, Comte R, Pechre JC. Prevention of vascular graft infection by rifampin bonding to a gelatin-sealed Dacron graft. Ann Vasc Surg 1991;5:408-12.
11. Lovering AM, MacGowan AP. A comparative study of the rifampicin binding and elution. Characteristics for collagen- and albumin-sealed vascular grafts. Eur J Vasc Endovasc Surg 1999;17:347-50.
12. D'Addato M, Curti T, Freyrie A, Agus GB, Bertini D, Biasi G. Prevention of early graft infection with rifampicin-bonded Gelseal grafts: a multicentre experimental study. Cardiovasc Surg 1994;2:254-8.
13. Lachapelle K, Graham AM, Symes JF. Antibacterial activity, antibiotic retention, and infection resistance of a rifampin-impregnated gelatin-sealed dacron graft. J Vasc Surg 1994;19:675-82.
14. Gahtan V, Esses GE, Bandyk DF, Nelson RT, Dupont E, Mills JL. Antistaphylococcal activity of rifampin-bonded gelatin-impregnated Dacron grafts. J Surg Res 1995;58:105-10.
15. Torsello G, Sandmann W, Gehrt A, Jungblut RM. In situ replacement of infected vascular prostheses with rifampin-soaked vascular grafts: early results. J Vasc Surg 1993;17:768-73.
16. D'Addato M, Curti T, Freyrie A. Prophylaxis of graft infection with rifampicin-bonded Gelseal graft: 2-year follow-up of a prospective clinical trial. Cardiovasc Surg 1996;4:200-4.
17. Torsello G, Sandmann W. Use of antibiotic-bonded grafts in vascular graft infection. Eur J Vasc Endovasc Surg 1997;14(Suppl A):84-7.
18. Bandyk DF, Bergamini TM, Kinney EV, Seabrook GR, Towne JB. In situ replacement of vascular prostheses infected by bacterial biofilms. J Vasc Surg 1991;13:575-83.
19. Towne JB, Seabrook GR, Bandyk DF, Freischlag JA, Edmiston CE. In situ replacement of arteral prosthesis infected by bacterial biofilms: long term follow up. J Vasc Surg 1994;19:226-35.
20. Hayes PD, Nasim A, London NJM, Sayers RD, Barrie WW, Bell PRF, et al. In situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience (1992 to 1998). J Vasc Surg 1999;30:92-8.
21. Vicaretti M, Hawthorne W, Ao PY, Fletcher JP. Does in situ replacement of a staphylococcal infected vascular graft with a rifampicin impregnated gelatin sealed Dacron graft reduce the incidence of subsequent infection? Int Angiol 2000;19:158-65.
22. National Committee for Clinical Labratory Standards. Performance standards for antimicrobial susceptibility testing; ninth informational supplement, NCCLS Document M2-A6. Villanova (PA): NCCLS; 1999.
23. Richmond JY, McKinney RW. Biosafety in microbiological and biomedical laboratories [online]. 4th edition. Bethesda (MD): National Institutes of Health; 1999. Available from: http://bmbl.od.nih.gov.
24. Yeager RA, Taylor LM, Moneta GL, Edwards JM, Nicoloff AD, McConnell DB, et al. Improved results with conventional management of infrarenal aortic infection. J Vasc Surg 1999;30:76-83.
25. Litzler PY, Thomas P, Danielou E, Lucq J, Jacques B, Frebourg N, et al. Bacterial resistance of refrigerated and cryopreserved aortic allografts in an experimental virulent infection model. J Vasc Surg 1999;29:1090-6.
26. Vogt PR, von Segesser LK, Goffin Y, Niederhäuser U, Genoni M, Künzli A, et al. Eradication of aortic infections with the use of cryopreserved arterial homografts. Ann Thorac Surg 1996;62:640-5.
27. Drury JK, Ashton TR, Cunningham JD, Maini R, Pollock JG. Experimental and clinical experience with a gelatin impregnated Dacron prosthesis. Ann Vasc Surg 1987;1:542-7.
28. Jeffrey JK, Lehman IR. Yeast mitochondrial RNA polymerase. J Biol Chem 1986;261:10340-7.
29. Ferraro MJ, Craig WA, Dudley MN, et al. Performance standards for antimicrobial disk susceptibility tests; approved standard. 7th edition. Wayre (PA): National Commitee for Clinical Laboratory Standard (NCCLS); 2001.
30. Marples RR, Cooke EM. Current problems with methicllin-resistant Stapylococcus aureus. J Hosp Infect 1988;11:381-92.